Bicarbonate and Dichloroacetate in Metastatic Breast Cancer
Author Information
Author(s): Ian F. Robey, Natasha K. Martin
Primary Institution: University of Arizona
Hypothesis
Can the combination of bicarbonate and dichloroacetate enhance the safety and efficacy of cancer treatment in a mouse model for metastatic breast cancer?
Conclusion
The combination therapy did not enhance the effects of chronic oral bicarbonate, and the efficacy of dichloroacetate as a cancer therapy is unpredictable.
Supporting Evidence
- Chronic oral administration of bicarbonate significantly increases urine pH in tumor-bearing mice.
- DB treatment resulted in significantly smaller mean tumor metastases compared to all other groups.
- Survival was longest in mice administered bicarbonate-based therapies.
- DCA monotherapy was not effective in reducing tumor size or metastases.
- Primary tumor re-occurrence was associated with survival rates.
Takeaway
This study looked at how two treatments, bicarbonate and dichloroacetate, affect mice with breast cancer. It found that while bicarbonate helps, adding dichloroacetate doesn't make it better.
Methodology
Mice with breast cancer were treated with bicarbonate, dichloroacetate, or a combination of both, and their survival and tumor growth were monitored.
Potential Biases
Potential bias in treatment effects due to the specific mouse model used.
Limitations
The study's findings may not be applicable to all cancer types, and the effects of DCA were inconsistent across different conditions.
Participant Demographics
Female severe combined immunodeficient (SCID) mice aged six to eight weeks.
Statistical Information
P-Value
p=0.03 for bicarbonate, p=0.01 for DB
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website